Literature DB >> 32724915

PURL: USPSTF expands options for cervical cancer screening.

Sonia Oyola1, Emily White VanGompel2.   

Abstract

Women ages 30 to 65 years now have a third cervical cancer screening option.

Entities:  

Mesh：

Year:  2020        PMID： 32724915      PMCID： PMC7492071     

Source DB:  PubMed          Journal:  J Fam Pract        ISSN： 0094-3509            Impact factor:   0.493


  7 in total

1.  Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:  Virginia A Moyer
Journal:  Ann Intern Med       Date:  2012-06-19       Impact factor: 25.391

2.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.

Authors:  Guglielmo Ronco; Paolo Giorgi-Rossi; Francesca Carozzi; Massimo Confortini; Paolo Dalla Palma; Annarosa Del Mistro; Bruno Ghiringhello; Salvatore Girlando; Anna Gillio-Tos; Laura De Marco; Carlo Naldoni; Paola Pierotti; Raffaella Rizzolo; Patrizia Schincaglia; Manuel Zorzi; Marco Zappa; Nereo Segnan; Jack Cuzick
Journal:  Lancet Oncol       Date:  2010-01-18       Impact factor: 41.316

3.  The impact of cervical cancer and dysplasia: a qualitative, multiethnic study.

Authors:  Kimlin T Ashing-Giwa; Marjorie Kagawa-Singer; Geraldine V Padilla; Judith S Tejero; Evana Hsiao; Rajinder Chhabra; Lucrecia Martinez; M Belinda Tucker
Journal:  Psychooncology       Date:  2004-10       Impact factor: 3.894

4.  Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.

Authors:  Susan J Curry; Alex H Krist; Douglas K Owens; Michael J Barry; Aaron B Caughey; Karina W Davidson; Chyke A Doubeni; John W Epling; Alex R Kemper; Martha Kubik; C Seth Landefeld; Carol M Mangione; Maureen G Phipps; Michael Silverstein; Melissa A Simon; Chien-Wen Tseng; John B Wong
Journal:  JAMA       Date:  2018-08-21       Impact factor: 56.272

Review 5.  Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

Authors:  Joy Melnikow; Jillian T Henderson; Brittany U Burda; Caitlyn A Senger; Shauna Durbin; Meghan S Weyrich
Journal:  JAMA       Date:  2018-08-21       Impact factor: 56.272

6.  A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial).

Authors:  Gina S Ogilvie; Dirk J van Niekerk; Mel Krajden; Ruth E Martin; Thomas G Ehlen; Kathy Ceballos; Stuart J Peacock; Laurie W Smith; Lisa Kan; Darrel A Cook; Wendy Mei; Gavin C E Stuart; Eduardo L Franco; Andrew J Coldman
Journal:  BMC Cancer       Date:  2010-03-24       Impact factor: 4.430

7.  Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.

Authors:  Guglielmo Ronco; Paolo Giorgi-Rossi; Francesca Carozzi; Massimo Confortini; Paolo Dalla Palma; Annarosa Del Mistro; Anna Gillio-Tos; Daria Minucci; Carlo Naldoni; Raffaella Rizzolo; Patrizia Schincaglia; Renza Volante; Marco Zappa; Manuel Zorzi; Jack Cuzick; Nereo Segnan
Journal:  J Natl Cancer Inst       Date:  2008-03-25       Impact factor: 13.506
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.